PLA2R1 and membranous glomerulonephritis: There is emerging evidence for the efficacy of Obinutuzumab in treating Rituximab-resistant membranous nephropathy, with several case series now published, primarily in PLA2R-positive membranous nephropathy.[10–13] A recent case-series has been published of Obinutuzumab as first-line treatment in untreated primary membranous nephropathy, with promising results [14].